From: The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study
Grade 3–4 adverse events
AG (n = 24), n (%)
FFX (n = 20), n (%)
P value
Peripheral neuropathy
5
0
0.030*
Neutropenia
6
0.676
Febrile neutropenia
1
0.895
Thrombocytopenia
2
0.328
Vomiting
3
0.213
Fatigue
0.552
Diarrhea
0.848